Cellontech and Kolon Pharmaceutical Collaborate on Joint Marketing of 'Katizol'

Cellontech, a subsidiary of SC Engineering, is expanding its influence in the domestic osteoarthritis market through consecutive joint marketing contract achievements for the intra-articular injection ‘CartiZol’.

Regenerative medicine specialized bio company Cellontech announced on the 13th that it has signed a joint marketing contract for CartiZol with Kolon Pharmaceutical.

Through this contract, both companies will cooperate to expand the sales of CartiZol in the domestic osteoarthritis treatment market. Cellontech will supply Kolon Pharmaceutical with two of the four CartiZol treatment options: ‘CartiZol Active (3-dose formulation)’ and ‘CartiZol Prime (5-dose formulation)’.

Kolon Pharmaceutical will launch CartiZol under the new product name ‘Carticure’ series. Carticure will be supplied to the market as ‘Carticure Shot3’ (3-dose formulation) and ‘Carticure Shot5’ (5-dose formulation). The product name Carticure is a compound word of ‘Cartilage’ and ‘Cure,’ meaning that it heals by injecting collagen into the joint cavity to coat and supplement damaged cartilage.

Founded in 1958, Kolon Pharmaceutical is a total healthcare specialized company. Since 2021, it has continuously launched various osteoarthritis treatments such as Levocozu (PDRN), Lepovi (PN), Tramol injection, Leostin tablets, and Celeco capsules, strengthening its sales and marketing capabilities in the orthopedic field.

A Kolon Pharmaceutical representative said, "Ahead of the Carticure sales, we are conducting active pre-marketing targeting domestic demand channels, enabling rapid market entry. With the launch of Carticure, we expect to strengthen arthritis treatment options and orthopedic product lineups, expand sales growth, and solidify our position in the domestic osteoarthritis treatment market."

The origin of Carticure, CartiZol, is the first collagen intra-articular injection developed domestically by Cellontech. CartiZol injects bio-collagen, a component of the surface layer (synovium) of articular cartilage tissue, into the joint cavity to supplement damaged articular cartilage. Unlike existing products that only relieve pain, it has differentiated competitiveness by aiding the natural healing process of articular cartilage. Additionally, the bio-collagen, which is the main ingredient of CartiZol and independently developed by Cellontech, is registered in the U.S. Food and Drug Administration (FDA) Drug Master File (DMF).

A Cellontech representative stated, “We expect to more effectively expand CartiZol’s market share by leveraging Kolon Pharmaceutical’s strong sales network and marketing capabilities. Based on CartiZol’s superior therapeutic efficacy and various treatment options, we will continue to strive to expand supply channels and increase sales.”

This content was produced with the assistance of AI translation services.